DNA Patent Question Tossed Back To Lower Court
This article was originally published in The Gray Sheet
Executive Summary
In the wake of the high court’s ruling in Mayo v. Prometheus, the Supreme Court orders the Federal Circuit to reconsider its decision that Myriad Genetics’ isolated BRCA genes are patentable.
You may also be interested in...
Patent Attorneys Vent Frustrations Over Supreme Court Diagnostics Rulings
Attorneys at a recent BIO-convened symposium were disgruntled and anxiety-ridden by two recent Supreme Court rulings on patent protection – the 2012 Mayo Collaborative Services v. Prometheus Laboratories Inc. decision and the 2013 The Association of Molecular Pathology v. Myriad Genetics Inc ruling.
Patent Attorneys Vent Frustrations Over Supreme Court Diagnostics Rulings
Attorneys at a recent BIO-convened symposium were disgruntled and anxiety-ridden by two recent Supreme Court rulings on patent protection – the 2012 Mayo Collaborative Services v. Prometheus Laboratories Inc. decision and the 2013 The Association of Molecular Pathology v. Myriad Genetics Inc ruling.
Supreme Court Overturns Personalized Medicine Patents, Creating Confusion In Diagnostics Realm
High court rules the processes covered by two patents to determine proper drug dosages based on metabolite concentrations do not transform unpatentable natural laws into patent-eligible applications.